GlassScriptPhysician profile
Anthony Castagno
NPI 1649545443
$3,946.00
in general payments reported to CMS, 2019-2025
14 companies · $80.32 in 2025
The $80.32 reported for 2025 was less than what a typical Surgical provider received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $723 · 2022: $1,205 · 2023: $1,375 · 2024: $564 · 2025: $80.32.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,019.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,018.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,732.61 | 2021-2023 | Xarelto |
| Pfizer INC. | $614.11 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $442.30 | 2021-2024 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $340.00 | 2021-2024 | Repatha |
| E.R. Squibb & Sons, L.L.C. | $241.41 | 2021-2024 | Camzyos, Eliquis |
| Abiomed | $238.41 | 2023-2025 | Impella |
| Novartis Pharmaceuticals Corporation | $113.72 | 2023-2024 | |
| Medtronic, INC. | $75.42 | 2021-2023 | Corevalve Evolut R |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $54.42 | 2024 | Lifevest |
| Getinge USA Sales, LLC | $22.55 | 2025 | Vasoview Hemopro 2 |
| Merck Sharp & Dohme LLC | $21.60 | 2024 | Verquvo |
| Edwards Lifesciences Corporation | $19.61 | 2023 | |
| Impulse Dynamics (USA) INC. | $16.49 | 2024 | Optimizer |
| Teleflex LLC | $13.35 | 2023 | Vascband |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Castagno listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.